Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Gynecologic 2Endocrine 2Thoracic 1NET 1Head & Neck 1Gastrointestinal 1CNS 1Breast 1

Conditions

Neuroendocrine Tumors 11Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Urogenital Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Parotid Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Microsatellite Instability 1Mesothelioma 1Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Small Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Carcinoid Tumor 1Breast Neoplasms 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Anus Neoplasms 1

Interventions

taxane 1pembrolizumab 1liposomal doxorubicin 1Vinorelbine 1RRx-001 1Quality of Life 1Pemetrexed 1Patient Reported Outcome Measures 1Paclitaxel 1PT-100 dipeptide 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Gemcitabine 1Etoposide 1Drug Therapy 1Cisplatin 1Carboplatin 1Biological Therapy 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × pembrolizumab × NET × Clear all
NCT03910660 2026-05-15

A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.

BioXcel Therapeutics Inc

Phase 1/2 Completed
98 enrolled
EndocrineGenitourinaryNET

Prostatic Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡